<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03262480</url>
  </required_header>
  <id_info>
    <org_study_id>MD/17.07.27</org_study_id>
    <nct_id>NCT03262480</nct_id>
  </id_info>
  <brief_title>The Stroke Volume Optimization of Goal Directed Fluid Therapy During Radical Cystectomy</brief_title>
  <official_title>Perioperative Goal Directed Fluid Therapy During Radical Cystectomy: the Impact of Stroke Volume Optimization vs Dynamic Central Venous Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although fluid therapy is of paramount value in anesthetic practice, there is no guideline&#xD;
      available for perioperative fluid management in major abdominal surgery. So, there is a need&#xD;
      to establish whether goal directed fluid therapy protocol is effective during radical&#xD;
      cystectomy and urinary diversion. A balance of perioperative fluid therapy is crucial, yet&#xD;
      the method to achieve this equilibrium remains a highly debated subject. Therefore, this&#xD;
      study will be designed to investigate the effects of two individualized goal directed fluid&#xD;
      therapy during radical cystectomy to encourage an effective circulating blood volume and&#xD;
      pressure. Accordingly, as a primary outcome, the investigators assume that stroke volume&#xD;
      optimization could maintain better perioperative hemodynamic stability with low incidence and&#xD;
      severity of hypotensive episodes together with achievement of maximal oxygenation. Hopefully&#xD;
      this regimen could help to decrease the possibility of perioperative tissue hypoperfusion and&#xD;
      the possible associated complications as a secondary outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study protocol:&#xD;
&#xD;
      Patients will be randomly assigned to one of two equal groups, according to&#xD;
      computer-generated randomization sequence into:&#xD;
&#xD;
        -  Stroke volume optimization group (SVO group).&#xD;
&#xD;
        -  Central venous pressure dynamic group(CVPdyngroup).&#xD;
&#xD;
      Stroke volume optimization group (SVO group):&#xD;
&#xD;
      Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4 (Voluven, Fresenius kabi,&#xD;
      Deutschland GmbH, Bad Homburg, Germany) will be administered within 10 minutes and stroke&#xD;
      volume response will be recorded .If stroke volume increase by more than 10 % for 20 minutes,&#xD;
      the aliquot will be repeated. No further aliquots will be given once stroke volume failed to&#xD;
      increase &gt;10%. The last stroke volume without rise of &gt; 10% will be defined as optimum stroke&#xD;
      volume (SVopt).When stroke volume decreases by 10% below (SVopt), this will be defined as&#xD;
      trigger stroke volume (SVT). Stroke volume will be followed every 30 minutes during surgery&#xD;
      and every 4 hours for 24 hours postoperatively .&#xD;
&#xD;
      Central venous pressure dynamic group (CVPdyn group):&#xD;
&#xD;
      Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4(Voluven) will be administered&#xD;
      within 10 minutes and CVP response will be recorded. If CVP failed to rise sustainably for&#xD;
      more than 2 mmHg for 20 minutes, the aliquot will be repeated. No further aliquots will be&#xD;
      given once CVP increases more than 2 mmHg above the recorded one.The last CVP with sustained&#xD;
      rise of&gt;2 mmHg will be defined as CVP maximum (CVPmax).When CVP decrease below (CVPmax)by 3&#xD;
      mmHg, this will be defined as trigger CVP (CVPT).CVP will be followed every 30 min during&#xD;
      surgery and every 4 hours for 24 hours postoperatively&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">December 10, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two groups:&#xD;
Stroke volume optimization group (SVO group).&#xD;
Central venous pressure dynamic group(CVPdyngroup).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>The management will be carried out by a member of research team only aware of allocation group. The attending anesthesiologist, surgeons and nursing staff will be totally blind of randomization schedule or the hydration regimen used. All postoperative clinical staff handling patient care will be also unaware of the aim of the work.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Perioperative hypotension</measure>
    <time_frame>perioperative</time_frame>
    <description>Mean arterial blood pressure &lt; 65mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal tissue oxygenation</measure>
    <time_frame>perioperative</time_frame>
    <description>Oxygen delivery index &gt; 550 ml/min/m2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medical postoperative complication</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>Acute kidney injury (AKI) . Postoperative serum creatinine value is either more than 1.5-fold or more than 0.3 mg/dl before surgery within 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical postoperative complication</measure>
    <time_frame>7-days postoperative</time_frame>
    <description>Nausea, vomiting, abdominal distension, anastomotic leakage, paralytic ileus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anesthetic postoperative complication</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>Cardiogenic pulmonary edema.Cardiac index &lt; 2.5 l/min/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical postoperative complication</measure>
    <time_frame>7-days postoperative</time_frame>
    <description>Wound infection and burst abdomen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory postoperative complication</measure>
    <time_frame>7-days postoperative</time_frame>
    <description>Pneumonia, acute respiratory distress, postoperative ventilation and ICU admission.length of ICU stay in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complication</measure>
    <time_frame>7-days postoperative</time_frame>
    <description>mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Radical Cystectomy</condition>
  <arm_group>
    <arm_group_label>Stroke volume optimization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4 (Voluven) will be administered within 10 minutes and stroke volume response will be recorded .If stroke volume increase by more than 10 % for 20 minutes, the aliquot will be repeated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Central venous pressure dynamic</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4(Voluven) will be administered within 10 minutes and CVP response will be recorded. If CVP failed to rise sustainably for more than 2 mmHg for 20 minutes, the aliquot will be repeated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stroke volume optimization</intervention_name>
    <description>Hemodynamic variables including stroke volume (SV), stroke volume variation (SVV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), systolic time ratio (STR), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be measured by Cardiac output non-invasive monitor (ICONTM, OSYPKA medical cardiotronic GMBH, Elixir, Germany). Heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP) and arterial oxygen saturation (Sao2) will be measured using HP monitor.&#xD;
If mean arterial blood pressure(MAP) drops below 65 mmHg despite achievement of SVopt and CVPmax in both groups, a bolus dose of 5 mg ephedrine will be given and repeated as needed .Norepinephrine will be given for persistent hypotension.Dobutamine 5 mic/kg/min will be started if cardiac index less than 2.5 l/m2.</description>
    <arm_group_label>Central venous pressure dynamic</arm_group_label>
    <arm_group_label>Stroke volume optimization</arm_group_label>
    <other_name>central venous pressure dynamic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients with American Society of Anesthesiologists (ASA) physical status I - II&#xD;
             scheduled for radical cystectomy and urinary diversion for muscle invasive urinary&#xD;
             bladder carcinoma .&#xD;
&#xD;
          -  Both sexes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients younger than 18 years&#xD;
&#xD;
          -  Body mass index (BMI) &lt; 25 and &gt;35.&#xD;
&#xD;
          -  Patients with any contraindications to epidural anesthesia (patient refusal, local&#xD;
             skin infection, previous spine surgery and coagulopathy).&#xD;
&#xD;
          -  Those with known allergy to local anesthetics.&#xD;
&#xD;
          -  Patients with major cardiovascular problems with ejection fraction &lt; 40 .&#xD;
&#xD;
          -  Renal impairment with serum creatinine &gt;1.8 mg/dl&#xD;
&#xD;
          -  Patients with hepatic dysfunction will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud M Othman, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura faculty of medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urology and nephrology center</name>
      <address>
        <city>Mansoura</city>
        <state>El-Dakahlia</state>
        <zip>+2050</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 14, 2017</study_first_submitted>
  <study_first_submitted_qc>August 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2017</study_first_posted>
  <last_update_submitted>December 20, 2020</last_update_submitted>
  <last_update_submitted_qc>December 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Mahmoud Mahmoud Othman</investigator_full_name>
    <investigator_title>professor of Anesthesia and surgical ICU</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

